Inicio>>Analytical Standards>>Dextromethorphan (hydrobromide hydrate)

Dextromethorphan (hydrobromide hydrate) (Synonyms: DXM, D-Methorphan)

Catalog No.GC43428

Dextrometorfano (DXM) es un morfinano dextrorrotatorio con similitud estructural a la levorfanol, codeína y morfina.

Products are for research use only. Not for human use. We do not sell to patients.

Dextromethorphan (hydrobromide hydrate) Chemical Structure

Cas No.: 6700-34-1

Tamaño Precio Disponibilidad Cantidad
50mg
33,00 $
Disponible
100mg
63,00 $
Disponible
500mg
259,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents Related Products

Dextromethorphan (DXM) is a dextratrorotatory morphinan with structural similarity to levorphanol, codeine, and morphine. Because of its strong antitussive effects, dextromethorphan is widely used as a cough suppressant. However, it does not provoke opioid activity as is characteristic of several other morphine derivatives. DXM binds to and inhibits NMDA (IC50 = 0.55 μM) and nicotinic receptors (IC50s = 0.7-3.9 μM) and blocks receptor-gated and voltage-gated calcium channels (IC50 = 60 μM) and voltage-gated sodium channels (IC50 = 78 μM). DXM has been used in multimodal analgesic therapies for acute and neuropathic pain.

Reseñas

Review for Dextromethorphan (hydrobromide hydrate)

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Dextromethorphan (hydrobromide hydrate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.